Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pravastatin + valsartan
- Development stage
- Unknown
- Lead developer
- Gachon University Gil Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A therapeutic combination of pravastatin, an HMG-CoA reductase inhibitor (statin), and valsartan, an angiotensin II type 1 receptor blocker (ARB). This specific combination (40 mg pravastatin and 160 mg valsartan) was investigated by researchers at Gachon University Gil Medical Center, led by Dr. Kwang Kon Koh, for the treatment of patients with comorbid hypertension and hypercholesterolemia. The combination aims to provide additive cardiovascular benefits, including improved endothelial function (flow-mediated dilation), increased insulin sensitivity, and reduced inflammatory markers, beyond the effects of either monotherapy. It is not a commercially marketed fixed-dose combination product but was evaluated in Phase 4 randomized clinical trials.
- Other names
- pravastatin and valsartan combination
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on pravastatin + valsartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pravastatin + valsartan.